Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 4.77
DCTH's Cash to Debt is ranked higher than
53% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. DCTH: 4.77 )
Ranked among companies with meaningful Cash to Debt only.
DCTH' s Cash to Debt Range Over the Past 10 Years
Min: 1.97  Med: No Debt Max: No Debt
Current: 4.77
Equity to Asset 0.13
DCTH's Equity to Asset is ranked lower than
95% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DCTH: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
DCTH' s Equity to Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.76 Max: 0.84
Current: 0.13
0.13
0.84
Interest Coverage N/A
DCTH's Interest Coverage is ranked higher than
76% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. DCTH: N/A )
Ranked among companies with meaningful Interest Coverage only.
DCTH' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
F-Score: 3
Z-Score: -10.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -884.87
DCTH's Operating margin (%) is ranked lower than
94% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. DCTH: -884.87 )
Ranked among companies with meaningful Operating margin (%) only.
DCTH' s Operating margin (%) Range Over the Past 10 Years
Min: -15569.65  Med: -2992.71 Max: -870.64
Current: -884.87
-15569.65
-870.64
Net-margin (%) -930.48
DCTH's Net-margin (%) is ranked lower than
94% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. DCTH: -930.48 )
Ranked among companies with meaningful Net-margin (%) only.
DCTH' s Net-margin (%) Range Over the Past 10 Years
Min: -14990.75  Med: -2732.2 Max: -841.67
Current: -930.48
-14990.75
-841.67
ROE (%) -164.85
DCTH's ROE (%) is ranked lower than
96% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. DCTH: -164.85 )
Ranked among companies with meaningful ROE (%) only.
DCTH' s ROE (%) Range Over the Past 10 Years
Min: -224.96  Med: -110.94 Max: -29.88
Current: -164.85
-224.96
-29.88
ROA (%) -75.02
DCTH's ROA (%) is ranked lower than
94% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. DCTH: -75.02 )
Ranked among companies with meaningful ROA (%) only.
DCTH' s ROA (%) Range Over the Past 10 Years
Min: -157.86  Med: -82.11 Max: -27.27
Current: -75.02
-157.86
-27.27
ROC (Joel Greenblatt) (%) -1187.38
DCTH's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. DCTH: -1187.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DCTH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -194983.33  Med: -1125.65 Max: -161.78
Current: -1187.38
-194983.33
-161.78
Revenue Growth (3Y)(%) 6.10
DCTH's Revenue Growth (3Y)(%) is ranked higher than
51% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. DCTH: 6.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DCTH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.1
Current: 6.1
0
6.1
EBITDA Growth (3Y)(%) -60.20
DCTH's EBITDA Growth (3Y)(%) is ranked lower than
98% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. DCTH: -60.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DCTH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.2  Med: -5.2 Max: 56.4
Current: -60.2
-60.2
56.4
EPS Growth (3Y)(%) -59.30
DCTH's EPS Growth (3Y)(%) is ranked lower than
97% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. DCTH: -59.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DCTH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.3  Med: -16.2 Max: 95.7
Current: -59.3
-59.3
95.7
» DCTH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DCTH Guru Trades in Q3 2015

Jim Simons 617,898 sh (+22.55%)
» More
Q4 2015

DCTH Guru Trades in Q4 2015

Jim Simons 647,998 sh (+4.87%)
» More
Q1 2016

DCTH Guru Trades in Q1 2016

Jim Simons 682,498 sh (+5.32%)
» More
Q2 2016

DCTH Guru Trades in Q2 2016

Jim Simons 754,998 sh (+10.62%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:SPLIF, OTCPK:PTLFD, OTCPK:IMLFF, OTCPK:NUVPF, OTCPK:KAYS, OTCPK:CYIG, OTCPK:PUFXF, NAS:MYOS, OTCPK:ULUR, OTCPK:RSPID, OTCPK:PCYN, NAS:BNTC, AMEX:IGC, OTCPK:TRGM, OTCPK:NRXGQ, OTCPK:AQSZF, NAS:CBYL, OTCPK:CVSI, OTCPK:RLMD, NAS:OCLS » details
Traded in other countries:DV32.Germany,
Delcath Systems Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver.

Delcath Systems Inc is a Delaware corporation, incorporated on August 5, 1988. The Company is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. It is a specialty pharmaceutical and medical device company developing its proprietary product-Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, its proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Its primary focus is on the execution of its clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. Its competitors include Covidian, Biocompatibles, Merit, CeleNova, SirTex, AngioDynamics, and many others. The Company currently holds eight U.S. utility patents, one U.S. design patent, six pending U.S. utility patent applications (one of which has been allowed), four issued foreign counterpart utility patents, six issued foreign counterpart design patents, and eight pending foreign counterpart patent applications (one of which has been allowed). The Company's products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.

Ratios

vs
industry
vs
history
P/B 1.06
DCTH's P/B is ranked higher than
85% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. DCTH: 1.06 )
Ranked among companies with meaningful P/B only.
DCTH' s P/B Range Over the Past 10 Years
Min: 0.38  Med: 1.09 Max: 6.25
Current: 1.06
0.38
6.25
P/S 2.81
DCTH's P/S is ranked higher than
51% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. DCTH: 2.81 )
Ranked among companies with meaningful P/S only.
DCTH' s P/S Range Over the Past 10 Years
Min: 2.14  Med: 18.88 Max: 1044.69
Current: 2.81
2.14
1044.69
EV-to-EBIT 0.01
DCTH's EV-to-EBIT is ranked higher than
100% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. DCTH: 0.01 )
Ranked among companies with meaningful EV-to-EBIT only.
DCTH' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.7  Med: 0.1 Max: 0.7
Current: 0.01
-2.7
0.7
EV-to-EBITDA 0.01
DCTH's EV-to-EBITDA is ranked higher than
100% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.21 vs. DCTH: 0.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
DCTH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.8  Med: 0.1 Max: 0.7
Current: 0.01
-2.8
0.7
Current Ratio 0.80
DCTH's Current Ratio is ranked lower than
94% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. DCTH: 0.80 )
Ranked among companies with meaningful Current Ratio only.
DCTH' s Current Ratio Range Over the Past 10 Years
Min: 0.58  Med: 6.32 Max: 67.13
Current: 0.8
0.58
67.13
Quick Ratio 0.78
DCTH's Quick Ratio is ranked lower than
85% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. DCTH: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
DCTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.58  Med: 6.13 Max: 67.13
Current: 0.78
0.58
67.13
Days Inventory 486.83
DCTH's Days Inventory is ranked lower than
96% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. DCTH: 486.83 )
Ranked among companies with meaningful Days Inventory only.
DCTH' s Days Inventory Range Over the Past 10 Years
Min: 436.89  Med: 693.6 Max: 5170.83
Current: 486.83
436.89
5170.83
Days Sales Outstanding 77.08
DCTH's Days Sales Outstanding is ranked higher than
50% of the 579 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.08 vs. DCTH: 77.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
DCTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.87  Med: 105.66 Max: 161.25
Current: 77.08
57.87
161.25
Days Payable 353.72
DCTH's Days Payable is ranked higher than
97% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.81 vs. DCTH: 353.72 )
Ranked among companies with meaningful Days Payable only.
DCTH' s Days Payable Range Over the Past 10 Years
Min: 224.37  Med: 698.02 Max: 8788.08
Current: 353.72
224.37
8788.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -65.50
DCTH's 3-Year Average Share Buyback Ratio is ranked lower than
95% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. DCTH: -65.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DCTH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -65.5  Med: -26 Max: -12.6
Current: -65.5
-65.5
-12.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.06
DCTH's Price/Tangible Book is ranked higher than
87% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. DCTH: 1.06 )
Ranked among companies with meaningful Price/Tangible Book only.
DCTH' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.65  Med: 4.81 Max: 42.99
Current: 1.06
0.65
42.99
Price/Median PS Value 0.15
DCTH's Price/Median PS Value is ranked higher than
98% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. DCTH: 0.15 )
Ranked among companies with meaningful Price/Median PS Value only.
DCTH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 1.13 Max: 45.22
Current: 0.15
0.15
45.22
Earnings Yield (Greenblatt) (%) No Debt
DCTH's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DCTH: No Debt )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DCTH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 145.3  Med: 283.15 Max: 190327.2
Current: No Debt
145.3
190327.2

More Statistics

Revenue (TTM) (Mil) $1.72
EPS (TTM) $ -11.45
Beta1.50
Short Percentage of Float12.75%
52-Week Range $2.80 - 10.88
Shares Outstanding (Mil)1.52

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) 0.01
EPS w/o NRI ($) 0.01
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for DCTH

Headlines

Articles On GuruFocus.com
Five NCAV Companies for Value Investors – August 2015 Aug 04 2015 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
Delcath Sponsors Ocular Melanoma Foundation Patient Retreat Sep 19 2016
Delcath Sponsors Ocular Melanoma Foundation Patient Retreat Sep 19 2016
Data Supporting CHEMOSAT Presented at the Cardiovascular and Interventional Radiology Society of... Sep 14 2016
Delcath To Present At The 2016 Aegis Growth Conference Sep 12 2016
Researchers at leiden univeristy medical center receive outstanding service award for Publication on... Sep 12 2016
DELCATH SYSTEMS, INC. Financials Aug 24 2016
Delcath Systems, Inc. :DCTH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 Aug 18 2016
Delcath Announces Second Quarter Financial Results Aug 16 2016
Delcath Announces Second Quarter Financial Results Aug 16 2016
DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report Aug 15 2016
DELCATH SYSTEMS, INC. Files SEC form 8-K, Other Events Aug 08 2016
DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... Jul 21 2016
Delcath Announces Acceptance Of Abstracts For Poster Presentation At CIRSE 2016 Jul 18 2016
Outcomes Study On Delcath's Melphalan/HDS In The Treatment Of Hepatic Metastases To Be Published In... Jul 07 2016
Outcomes Study On Delcath's Melphalan/HDS In The Treatment Of Hepatic Metastases To Be Published In... Jul 07 2016
European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European... Jul 06 2016
European Data Supporting Survival Benefit With Delcath's CHEMOSAT System Presented At 6th European... Jul 06 2016
Delcath European Patient Education Website Receives Prestigious Digital Health Award Jun 23 2016
Delcath European Patient Education Website Receives Prestigious Digital Health Award Jun 23 2016
DELCATH SYSTEMS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... Jun 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)